

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1500 Session of 2011

INTRODUCED BY BEAR, BARRAR, SANTONI, BENNINGHOFF, AUMENT, BAKER, BOBACK, BOYD, CALTAGIRONE, CAUSER, COHEN, D. COSTA, COX, CREIGHTON, CUTLER, DAVIS, DELOZIER, DENLINGER, DeWEESE, DONATUCCI, EMRICK, EVERETT, FARRY, FLECK, GEIST, GEORGE, GIBBONS, GILLEN, GINGRICH, GOODMAN, GRELL, GROVE, HACKETT, HARRIS, HEFFLEY, HENNESSEY, HICKERNELL, HUTCHINSON, KILLION, KORTZ, MAJOR, MARSHALL, METCALFE, MICCARELLI, MICOZZIE, MILLARD, MILLER, MILNE, MOUL, MURT, O'NEILL, PERRY, PETRI, PICKETT, PYLE, RAPP, READSHAW, REED, ROCK, SAYLOR, SCAVELLO, STEPHENS, SWANGER, TALLMAN, TAYLOR, VULAKOVICH AND WATSON, MAY 9, 2011

AS AMENDED ON THIRD CONSIDERATION, IN SENATE, APRIL 2, 2012

AN ACT

1 Amending Title 51 (Military Affairs) of the Pennsylvania
2 Consolidated Statutes, consolidating the Long-Term Care
3 Patient Access to Pharmaceuticals Act; further providing for
4 declaration of policy, for definitions and for third-party
5 drugs in long-term care facilities; and making a related
6 repeal.

7 The General Assembly of the Commonwealth of Pennsylvania
8 hereby enacts as follows:

9 Section 1. Title 51 of the Pennsylvania Consolidated
10 Statutes is amended by adding a chapter to read:

11 CHAPTER 95

12 LONG-TERM CARE PATIENT ACCESS TO PHARMACEUTICALS

13 Sec.

14 9501. Scope of chapter.

15 9502. Declaration of policy.

1 9503. Definitions.
2 9504. State Board of Pharmacy.
3 9505. Third-party drugs in long-term care facilities.
4 9506. Recordkeeping.
5 9507. Fee.
6 9508. Civil liability and unprofessional conduct.
7 § 9501. Scope of chapter.

8 This chapter relates to long-term care patient access to
9 pharmaceuticals.

10 § 9502. Declaration of policy.

11 The General Assembly finds and declares as follows:

12 (1) A mechanism is to be provided through which patients
13 who have the ability to acquire lower cost drugs through the
14 United States Department of Veterans Affairs have access to
15 those drugs if they reside in a long-term care facility.

16 (2) The mechanism is to be provided by permitting the
17 pharmacy within the long-term care facility or which has a
18 contract with the long-term care facility to:

19 (i) receive the lower cost drugs directly from the
20 United States Department of Veterans Affairs drug benefit
21 program in the patient's name; and

22 (ii) repackage and relabel those drugs so they may
23 be dispensed in unit doses to patients in a long-term
24 care facility in compliance with the Food and Drug
25 Administration, the United States Pharmacopeia and the
26 long-term care facility's policies and procedures.

27 (3) This chapter shall be interpreted and construed to
28 effectuate the following purposes:

29 (i) To provide for the care, protection and
30 treatment of patients in long-term care facilities by

1 allowing them to utilize the drug benefit provided by the
2 United States Department of Veterans Affairs.

3 (ii) Consistent with the care, protection and
4 treatment of patients in long-term care facilities, to
5 provide a means by which a long-term care pharmacy, ←
6 WITHIN THE LONG-TERM CARE FACILITY OR THAT HAS A CONTRACT
7 WITH THE LONG-TERM CARE FACILITY, may:

8 (A) accept, on behalf of the patient, drugs
9 received directly from the United States Department
10 of Veterans Affairs; and

11 (B) repackage and relabel those drugs so that
12 the patient may receive them in a unit dose in
13 compliance with the Food and Drug Administration, the
14 United States Pharmacopeia and the long-term care
15 facility's policies and procedures.

16 (iii) To provide a means through which this chapter
17 is executed and enforced and in which long-term care
18 facilities, pharmacists, drug source facilities and
19 pharmaceutical providers may implement this chapter.

20 (4) Only individuals eligible for benefits provided by
21 the United States Department of Veterans Affairs are eligible
22 for the program under this chapter.

23 § 9503. Definitions.

24 The following words and phrases when used in this chapter
25 shall have the meanings given to them in this section unless the
26 context clearly indicates otherwise:

27 "Board." The State Board of Pharmacy.

28 "Drug source facility." A facility:

29 (1) where drugs are lawfully manufactured, dispensed or
30 distributed; and

1 (2) which is:

2 (i) operated by or under contract with the United
3 States Department of Veterans Affairs; or

4 (ii) approved by the United States Department of
5 Veterans Affairs.

6 "Lockbox." A cabinet, safe, container or other structure to
7 contain medications that shall be securely locked, substantially
8 constructed and accessible only to the pharmacist or his
9 representative as authorized by the regulations of the State
10 Board of Pharmacy.

11 "Long-term care facility." A long-term care nursing facility
12 as defined in section 802.1 of the act of July 19, 1979
13 (P.L.130, No.48), known as the Health Care Facilities Act.

14 "Means." The placement of a lockbox at a location at the
15 long-term care facility.

16 "Pharmaceutical provider." An entity that employs a
17 pharmacist.

18 § 9504. State Board of Pharmacy.

19 The board has the following powers and duties:

20 (1) Develop the form required by section 9505(b)(3) and
21 (4) (relating to third-party drugs in long-term care
22 facilities).

23 (2) Publish a notice in the Pennsylvania Bulletin that
24 the form has been developed.

25 § 9505. Third-party drugs in long-term care facilities.

26 (a) Authority.--Notwithstanding any other provision of law,
27 all of the following may dispense a drug acquired from a drug
28 source facility outside the long-term care facility to a patient
29 of a long-term care facility:

30 (1) A pharmacist employed by a long-term care facility.

1 (2) A pharmacy that contracts with a long-term care
2 facility to fill prescriptions for patients of the long-term
3 care facility.

4 (b) Unit dose.--A person authorized under subsection (a) to
5 dispense a drug shall repackage, relabel and dispense the drug
6 in a unit dose if all of the following conditions are met:

7 (1) The drug is obtained from a drug source facility.

8 (2) There is a prescription for the drug.

9 (3) The prescriber has signed a form authorizing the
10 long-term care facility to administer a drug from a drug
11 source facility outside the long-term care facility.

12 (4) The patient has signed a form authorizing the long-
13 term care facility to administer a drug from a drug source
14 facility outside the long-term care facility and provided
15 payment information for payment of the related fees to the
16 pharmacy. In the case of a minor or a patient who is unable
17 to sign the form, a parent, a guardian, an agent acting under
18 a power of attorney or a family member is authorized to sign
19 the form. The form must explain that a person authorized
20 under subsection (a) to dispense a drug from a drug source
21 facility outside the long-term care facility:

22 (i) is required to go through the process of
23 repackaging and relabeling the drug;

24 (ii) may charge a fee for repackaging and relabeling
25 the drug, including the amount of the fee and the
26 frequency of its assessment; and

27 (iii) has immunity from civil liability arising from
28 dispensation of the drug if the person properly
29 repackages and relabels the drug as set forth in section
30 9508 (relating to civil liability and unprofessional

conduct).

(5) The nursing facility attending physician has issued an order continuing the patient's medical regime.

(6) The repackaging is in compliance with the Food and Drug Administration, the United States Pharmacopeia and the long-term care facility's policies and procedures.

(7) The United States Department of Veterans Affairs provides the drug directly to the pharmacy in the long-term care facility in the patient's name or by mailing it to a lockbox located at the long-term care facility in the patient's name and with the following information in preparation for the repackaging and relabeling:

(i) The name and address of the dispensing pharmacy.

(ii) (Reserved).

(iii) (Reserved).

(iv) A copy of the original prescription upon request.

(v) The date the drug was dispensed.

(vi) Directions for use, contraindications and other materials required by law to be provided to the patient.

(7.1) A PHARMACIST MUST BE HELD RESPONSIBLE FOR HIS ACTIVITY OR ACTIVITY PERFORMED UNDER HIS SUPERVISION OR AUTHORIZATION.

(8) The pharmacist manager of the ~~long-term care~~ pharmacy, WITHIN THE LONG-TERM CARE FACILITY OR THAT HAS A CONTRACT WITH THE LONG-TERM CARE FACILITY, responsible for access to the lockbox shall be responsible for the following:

(i) Reviewing and approving written policies and procedures for lockbox operation, safety, security, accuracy, access and patient confidentiality.

1 (ii) Ensuring that medications received at the
2 lockbox are inspected for expiration date, misbranding
3 and physical integrity and ensuring that the lockbox is
4 inspected for security and accountability every month.

5 (iii) Inspecting medications received at the lockbox
6 to determine if:

7 (A) the original contents have deteriorated
8 significantly due to heat, cold fermentation or
9 prolonged agitation; or

10 (B) the sensors indicate the integrity of the
11 drug was compromised if the drugs were shipped in a
12 manner that would preserve the integrity of the drug,
13 such as cold packs or other temperature control
14 devices.

15 (iv) Assigning, discontinuing or changing authorized
16 personnel access to the lockbox.

17 (v) Ensuring that an accountability record is
18 maintained in accordance with the written policies and
19 procedures of operation.

20 (vi) Ensuring compliance with the applicable
21 provisions of Federal and State law.

22 § 9506. Recordkeeping.

23 For each drug dispensed in accordance with section 9505(a)
24 (relating to third-party drugs in long-term care facilities),
25 the person authorized to dispense the drug and the long-term
26 care facility shall maintain a record for at least two years of
27 all of the items specified in section 9505(b)(7).

28 § 9507. Fee.

29 A person authorized under section 9505(a) (relating to third-
30 party drugs in long-term care facilities) to dispense a drug may

charge no more than the maximum dispensing fee authorized by the
Department of Public Welfare regulations under the medical
assistance program.

§ 9508. Civil liability and unprofessional conduct.

(a) Repackaging and relabeling.--A person authorized under
section 9505(a) (relating to third-party drugs in long-term care
facilities) to dispense a drug shall be immune from civil
liability arising out of dispensation of the drug if the person
properly repackages and relabels a drug based on the information
received from the original drug source facility.

(b) Administration of drug.--A long-term care facility or an
employee or agent of a long-term care facility that properly
administers a drug from a person authorized under section
9505(a) to dispense the drug shall be immune from civil
liability arising out of administration of the drug.

(c) Unprofessional conduct.--A pharmacist authorized under
section 9505(a) to dispense a drug who properly relabels and
repackages the drug shall not be deemed to have engaged in
unprofessional conduct under section 5(9) of the act of
September 27, 1961 (P.L.1700, No.699), known as the Pharmacy
Act.

Section 2. Repeals are as follows:

(1) The General Assembly declares that the repeal under
paragraph (2) is necessary to effectuate the addition of 51
Pa.C.S. Ch. 95.

(2) The act of October 9, 2008 (P.L.1413, No.114), known
as the Long-Term Care Patient Access to Pharmaceuticals Act,
is repealed.

Section 3. The addition of 51 Pa.C.S. Ch. 95 is a
continuation of the act of October 9, 2008 (P.L.1413, No.114),

known as the Long-Term Care Patient Access to Pharmaceuticals Act. The following apply:

(1) Except as otherwise provided in 51 Pa.C.S. Ch. 95, all activities initiated under the Long-Term Care Patient Access to Pharmaceuticals Act shall continue and remain in full force and effect and may be completed under 51 Pa.C.S. Ch. 95. Orders, regulations, rules and decisions which were made under the Long-Term Care Patient Access to Pharmaceuticals Act and which are in effect on the effective date of section 2 of this act shall remain in full force and effect until revoked, vacated or modified under 51 Pa.C.S. Ch. 95. Contracts, obligations and collective bargaining agreements entered into under the Long-Term Care Patient Access to Pharmaceuticals Act are not affected nor impaired by the repeal of the Long-Term Care Patient Access to Pharmaceuticals Act.

(2) Except as set forth in paragraph (3), any difference in language between 51 Pa.C.S. Ch. 95 and the Long-Term Care Patient Access to Pharmaceuticals Act is intended only to conform to the style of the Pennsylvania Consolidated Statutes and is not intended to change or affect the legislative intent, judicial construction or administration and implementation of the Long-Term Care Patient Access to Pharmaceuticals Act.

(3) Paragraph (2) does not apply to the addition of the following provisions of Title 51:

(i) Section 9502(3)(ii).

(ii) The definitions of "lockbox" and "means" in section 9503.

(iii) Section 9505(b)(7) introductory paragraph,

1 (ii), (iii) and (iv) and (8).

2 Section 4. This act shall take effect as follows:

3 (1) The following provisions shall shall take effect
4 immediately:

5 (i) Section 3 of this act.

6 (ii) This section.

7 (2) The remainder of this act shall take effect in 60
8 days.